NO322682B1 - Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer - Google Patents
Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer Download PDFInfo
- Publication number
- NO322682B1 NO322682B1 NO20051467A NO20051467A NO322682B1 NO 322682 B1 NO322682 B1 NO 322682B1 NO 20051467 A NO20051467 A NO 20051467A NO 20051467 A NO20051467 A NO 20051467A NO 322682 B1 NO322682 B1 NO 322682B1
- Authority
- NO
- Norway
- Prior art keywords
- gemcitabine
- oral dosage
- dosage form
- dosage forms
- pharmaceutically acceptable
- Prior art date
Links
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical class O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title claims abstract description 43
- 239000006186 oral dosage form Substances 0.000 title claims abstract description 16
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 12
- 201000011510 cancer Diseases 0.000 title claims abstract description 10
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 43
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 21
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 claims description 21
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 21
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 3
- 239000000969 carrier Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- -1 gemcitabine ester Chemical class 0.000 claims 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 abstract description 3
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940020967 gemzar Drugs 0.000 description 2
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940108623 eicosenoic acid Drugs 0.000 description 1
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20051467A NO322682B1 (no) | 2005-03-18 | 2005-03-18 | Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer |
| UAA200711518A UA90893C2 (ru) | 2005-03-18 | 2006-03-07 | Пероральная дозированная форма производных гемцитабина |
| US11/908,364 US20080280851A1 (en) | 2005-03-18 | 2006-03-07 | Oral Dosage Forms of Gemcitabine Derivatives |
| CA002600399A CA2600399A1 (fr) | 2005-03-18 | 2006-03-07 | Formes de dosage oral de derives de gemcitabine |
| PCT/NO2006/000085 WO2006098628A1 (fr) | 2005-03-18 | 2006-03-07 | Formes de dosage oral de derives de gemcitabine |
| NZ561377A NZ561377A (en) | 2005-03-18 | 2006-03-07 | Oral dosage forms of gemcitabine derivatives |
| JP2008501829A JP2008533135A (ja) | 2005-03-18 | 2006-03-07 | ゲムシタビン誘導体の経口投薬形態 |
| EP06716760A EP1858527A4 (fr) | 2005-03-18 | 2006-03-07 | Formes de dosage oral de derives de gemcitabine |
| KR1020077023828A KR20070120539A (ko) | 2005-03-18 | 2006-03-07 | 겜시타빈 유도체의 경구 제형 |
| RU2007138582/15A RU2007138582A (ru) | 2005-03-18 | 2006-03-07 | Пероральные дозированные формы производных гемцитабина |
| AU2006223757A AU2006223757A1 (en) | 2005-03-18 | 2006-03-07 | Oral dosage forms of gemcitabine derivatives |
| IL185866A IL185866A0 (en) | 2005-03-18 | 2007-09-10 | Oral dosage forms of gemcitabine derivatives |
| ZA200707979A ZA200707979B (en) | 2005-03-18 | 2007-09-17 | Oral dosage forms of Gemcitabine derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20051467A NO322682B1 (no) | 2005-03-18 | 2005-03-18 | Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20051467D0 NO20051467D0 (no) | 2005-03-18 |
| NO322682B1 true NO322682B1 (no) | 2006-11-27 |
Family
ID=35267108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051467A NO322682B1 (no) | 2005-03-18 | 2005-03-18 | Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080280851A1 (fr) |
| EP (1) | EP1858527A4 (fr) |
| JP (1) | JP2008533135A (fr) |
| KR (1) | KR20070120539A (fr) |
| AU (1) | AU2006223757A1 (fr) |
| CA (1) | CA2600399A1 (fr) |
| IL (1) | IL185866A0 (fr) |
| NO (1) | NO322682B1 (fr) |
| NZ (1) | NZ561377A (fr) |
| RU (1) | RU2007138582A (fr) |
| UA (1) | UA90893C2 (fr) |
| WO (1) | WO2006098628A1 (fr) |
| ZA (1) | ZA200707979B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8497292B2 (en) * | 2005-12-28 | 2013-07-30 | Translational Therapeutics, Inc. | Translational dysfunction based therapeutics |
| WO2010039039A1 (fr) * | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Formulations orales de dérivés de gemcitabine |
| CN101525361B (zh) | 2009-04-21 | 2010-11-17 | 济南圣鲁金药物技术开发有限公司 | 基于吉西他滨结构的前药及其合成方法及应用 |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| WO2013009701A2 (fr) | 2011-07-08 | 2013-01-17 | The University Of North Carolina At Chapel Hill | Nanoparticules de métal-bisphosphonate pour thérapie anticancéreuse et imagerie, ainsi que pour traiter des troubles des os |
| CN102432654A (zh) * | 2011-09-26 | 2012-05-02 | 宋云龙 | 吉西他滨酰胺衍生物及其制备方法和用途 |
| BR112015010941A2 (pt) | 2012-11-13 | 2017-07-11 | Boyen Therapeutics Inc | pró-fármacos de gemcitabina e suas utilizações |
| WO2015069926A1 (fr) | 2013-11-06 | 2015-05-14 | The University Of Chicago | Vecteurs nanométriques pour l'administration ou la co-administration d'agents chimiothérapeutiques, d'acides nucléiques et de photosensibilisateurs |
| US10463684B2 (en) | 2014-01-29 | 2019-11-05 | Board Of Regents, The Uneversety Of Texas System | Nucleobase analogue derivatives and their applications |
| WO2017201528A1 (fr) | 2016-05-20 | 2017-11-23 | The University Of Chicago | Nanoparticules pour chimiothérapie, thérapie ciblée, thérapie photodynamique, immunothérapie et n'importe quelle combinaison de ces dernières |
| CN107184592A (zh) * | 2017-05-17 | 2017-09-22 | 广东艾时代生物科技有限责任公司 | 吉西他滨在制备治疗类风湿性关节炎药物中的应用 |
| EP3638367A4 (fr) | 2017-08-02 | 2021-07-21 | The University of Chicago | Couches organométalliques nanométriques et nanoplaques organométalliques pour thérapie photodynamique induite par rayons x, radiothérapie, thérapie radiodynamique, chimiothérapie, immunothérapie, et toute combinaison de celles-ci |
| AU2019216531A1 (en) | 2018-02-02 | 2020-09-24 | Maverix Oncology, Inc. | Small molecule drug conjugates of gemcitabine monophosphate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1327358C (fr) * | 1987-11-17 | 1994-03-01 | Morio Fujiu | Derives fluorocytidine |
| DE69812934T2 (de) * | 1997-01-24 | 2004-01-29 | Conpharma As Oslo | Gemcitabin-derivate |
| WO2004041203A2 (fr) * | 2002-11-04 | 2004-05-21 | Xenoport, Inc. | Promedicaments de gemcitabine, leurs compositions pharmaceutiques et leurs utilisations |
-
2005
- 2005-03-18 NO NO20051467A patent/NO322682B1/no not_active IP Right Cessation
-
2006
- 2006-03-07 AU AU2006223757A patent/AU2006223757A1/en not_active Abandoned
- 2006-03-07 JP JP2008501829A patent/JP2008533135A/ja active Pending
- 2006-03-07 WO PCT/NO2006/000085 patent/WO2006098628A1/fr active Application Filing
- 2006-03-07 RU RU2007138582/15A patent/RU2007138582A/ru not_active Application Discontinuation
- 2006-03-07 CA CA002600399A patent/CA2600399A1/fr not_active Abandoned
- 2006-03-07 EP EP06716760A patent/EP1858527A4/fr not_active Withdrawn
- 2006-03-07 NZ NZ561377A patent/NZ561377A/en not_active IP Right Cessation
- 2006-03-07 UA UAA200711518A patent/UA90893C2/ru unknown
- 2006-03-07 US US11/908,364 patent/US20080280851A1/en not_active Abandoned
- 2006-03-07 KR KR1020077023828A patent/KR20070120539A/ko not_active Application Discontinuation
-
2007
- 2007-09-10 IL IL185866A patent/IL185866A0/en unknown
- 2007-09-17 ZA ZA200707979A patent/ZA200707979B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200707979B (en) | 2008-11-26 |
| US20080280851A1 (en) | 2008-11-13 |
| NO20051467D0 (no) | 2005-03-18 |
| IL185866A0 (en) | 2008-01-06 |
| WO2006098628A1 (fr) | 2006-09-21 |
| UA90893C2 (ru) | 2010-06-10 |
| RU2007138582A (ru) | 2009-04-27 |
| NZ561377A (en) | 2009-10-30 |
| JP2008533135A (ja) | 2008-08-21 |
| AU2006223757A1 (en) | 2006-09-21 |
| EP1858527A4 (fr) | 2010-10-27 |
| EP1858527A1 (fr) | 2007-11-28 |
| KR20070120539A (ko) | 2007-12-24 |
| CA2600399A1 (fr) | 2006-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO322682B1 (no) | Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer | |
| JP7417658B2 (ja) | 癌治療のためのシタラビンコンジュゲート | |
| US20070225248A1 (en) | Oral dosage forms of gemcitabine derivatives | |
| CA2602573C (fr) | Agent protecteur pour la cellule neuronale retinienne contenant un derive de prostaglandine f2 .alpha. comme ingredient actif | |
| JP6546367B1 (ja) | がん治療薬 | |
| JP3192141B2 (ja) | 抗うつ剤 | |
| ES2384333T3 (es) | Composiciones farmacéuticas que tienen perfiles de disolución mejorados para fármacos poco solubles | |
| CA2321547A1 (fr) | Derives de l'indole et compositions medicales les renfermant | |
| JP2005512946A5 (fr) | ||
| FR3056108B1 (fr) | Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif | |
| US20230046869A1 (en) | Therapeutic combinations of orally administered docetaxel and a p-gp inhibitor for the treatment of cancer | |
| CN113301884A (zh) | 非水性化疗口服悬浮液 | |
| US20030139373A1 (en) | Method for cancer therapy | |
| US12064445B2 (en) | Cytarabine conjugates for cancer therapy | |
| JP2021533107A (ja) | 癌を治療するための併用療法 | |
| RU2471486C2 (ru) | Противоопухолевое средство для непрерывного внутривенного введения, содержащее цитидиновое производное | |
| JP810H (ja) | 抗腫瘍剤組成物 | |
| WO2021172490A1 (fr) | Médicament combiné, et médicament prévenant ou inhibant l'apparition de résistance à un antimétabolite de pyrimidine | |
| CN1144592C (zh) | 低胃肠毒性喜树碱衍生物的应用 | |
| HUT77379A (hu) | Azaspirán vegyületek alkalmazása hozzászokásos fertőzések kezelésére | |
| WO2004073719A1 (fr) | Traitement combine comprenant un derive d'indolopyrrolocarbazole et un autre agent antitumoral | |
| CA2388979A1 (fr) | Traitement ou prevention de l'hypotension et du choc a l'aide d'un derive de l'imidazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |